Scientific publications

• 2026

  Author	Title	Journal	Link
  Nagelschmitz, J. et al.	Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects	Br J of Clin Pharmacol, 1-14 (2026)	https://doi.org/10.1002/bcp.70668
  Edwards, M. et al.	ABHD2 activity is not required for the non-genomic action of progesterone on human sperm	Human Reproduction, 41, 8, 1409-1419 (2026)	https://doi.org/10.1093/humrep/deag085
  Zehrer, A. et al.	Enhancing tofacitinib's therapeutic efficacy in murine arthritis with a synbiotic formulation comprising Bacillus megaterium DSM 32963 and an Omega-3 fatty acid lysine salt	Front Immunol, 16, 1540878 (2026)	https://doi.org/10.3389/fimmu.2025.1540878
  Andersen, L. et al.	European bioanalysis forum recommendations for strengthening bioanalytical method transfer and validation through collaborative interactions	Bioanalysis, 1-4 (2026)	https://doi.org/10.1080/17576180.2026.2668968
  Hofmann S. et al.	Quantifying diclofenac – proven in theory, problematic in practice	Bioanalysis, 1-6 (2026)	https://doi.org/10.1080/17576180.2026.2677733
  Langer, G. et al.	Identification of the piperidyl urea derivative BAY-439 as a potent and selective inhibitor of human phospholipase A2 group V (hPLA2-G5) for the treatment of inflammatory pain	J Med Chem (2026)	https://doi.org/10.1021/acs.jmedchem.6c00488
  Freiherr von Scholley, G. L. et al.	Structural analysis of the flexibility of the Ubl2 domain within the papain-like protease of SARS-CoV-2	Acta Crystallogr F Struct Biol Commun, 82, 6, 222-230 (2026)<	https://doi.org/10.1107/S2053230X26003699
  Kosonen, R. et al.	Tau T205 phosphorylation modulates engram cell recruitment and remote memory in mice	Nat Commun (2026)	https://doi.org/10.1038/s41467-026-73207-9
  Lang, B. et al.	Structure elucidation and initial characterisation of a N-glucuronide metabolite (M1) of tuvusertib	Eur J Drug Metab Pharmacokinet (2026)	https://doi.org/10.1007/s13318-026-01006-0
  Caravella, J. A. et al.	Design of cyclic vinyl sulfones as WRN covalent inhibitors from non-covalent binders	J Med Chem, 69, 10, 12430–12448 (2026)	https://doi.org/10.1021/acs.jmedchem.6c00328
  Stenglein, S. et al.	Safety, tolerability, pharmacokinetics and pharmacodynamics of zapnometinib: results from a phase I clinical study	Front Pharmacol 17, 1743230 (2026)	https://doi.org/10.3389/fphar.2026.1743230
  Theis, T. et al.	Strategic key performance indicators for AI in lead optimisation	ChemMedChem, 21, 6, e202501089 (2026)	https://doi.org/10.1002/cmdc.202501089
  Cowan, K. J. et al.	From 3-tier to adaptive immunogenicity testing strategies: recommendations from the European Bioanalysis Forum	Bioanalysis, 18, 3, 217-226 (2026)	https://doi.org/10.1080/17576180.2026.2641928
  Kemmer, C. et al.	Single-ascending and multiple-ascending dose study of the pharmacokinetics, safety and tolerability of BV100 (rifabutin for infusion) in healthy volunteers	Antimicrob Agents Chemother, 70, 4, e0158225 (2026)	https://doi.org/10.1128/aac.01582-25
  Duller, S. et al.	Chemical characterisation of Nurexan: composition of a multi-component natural veterinary medicinal product	Front Vet Sci, 13, 1769201 (2026)	https://doi.org/10.3389/fvets.2026.1769201
  Herasymenko, O. et al.	CACHE Challenge #3: targeting the Nsp3 macrodomain of SARS-CoV-2	J Chem Inf Model, 66, 3, 1566-1581 (2026)	https://doi.org/10.1021/acs.jcim.5c02441
  Moura-Assis A. et al.	Identification of a thermogenic target in the dorsal raphe nucleus for weight management in mice	Nat Commun, 17, 1295 (2026)	https://doi.org/10.1038/s41467-025-68056-x
  Siegel, F. et al.	Sevabertinib, a reversible HER2 inhibitor with activity in lung cancer	Cancer Discov, 16, 1, 81-94 (2026)	https://doi.org/10.1158/2159-8290.CD-25-0605

• 2025

  Author	Title	Journal	Link
  Alaimo, C. et al.	Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: a first-in-human phase I/II randomised and controlled study	J Infect Dis, 233, 2, e342-e351 (2025)	https://doi.org/10.1093/infdis/jiaf600
  Eberspaecher, U. et al.	Polo-like kinase 1-inhibitor co-complex structures via the surface-entropy reduction approach and a DARPin-assisted approach	Acta Crystallogr D Struct Biol, 81, 12, 718-733 (2025)	https://doi.org/10.1107/S2059798325009325
  Timmerman, P. et al.	Beyond contracts: principles for Pharma-CRO collaboration from the European Bioanalysis Forum	Bioanalysis, 1-5 (2025)	https://doi.org/10.1080/17576180.2025.2582422
  Siegel, F. et al.	Sevabertinib, a reversible HER2 inhibitor with activity in lung cancer	Cancer Discov, OF1-OF14 (2025)	https://doi.org/10.1158/2159-8290.CD-25-0605
  Timmerman, P. et al.	European Bioanalysis Forum recommendation on embracing a context-of-use-driven scientific validation for chromatographic assays in the light of ICH M10.	Bioanalysis 1-10 (2025)	https://doi.org/10.1080/17576180.2025.2555774
  Herasymenko, O. et al.	CACHE challenge #2: targeting the RNA site of the SARS-CoV-2 helicase Nsp13.	J Chem Inf Model, 65, 13, 6884-6898 (2025)	https://doi.org/10.1021/acs.jcim.5c00535
  Hughes, R. et al.	Use of surrogate matrices in bioanalytical preclinical safety testing using immunoassay methods: a recommendation from the European Bioanalysis Forum.	Bioanalysis, 17, 14, 893-898 (2025)	https://doi.org/10.1080/17576180.2025.2545136
  Timmerman, P. et al.	Why traditional validation may fall short for artificial intelligence in bioanalysis: a perspective from the European Bioanalysis Forum.	Bioanalysis, 17, 13, 835-837 (2025)	https://doi.org/10.1080/17576180.2025.2535219
  Strotmann, R. et al.	Sensitivity of tepotinib to inhibitors or inducers of CYP3A4 and P-Gp: drug interaction studies and physiologically-based pharmacokinetic analysis.	Clin Transl Sci, 18, 7, e70273 (2025)	https://doi.org/10.1111/cts.70273
  Zehrer, A. et al.	Enhancing tofacitinib's therapeutic efficacy in murine arthritis with a synbiotic formulation comprising Bacillus megaterium DSM 32963 and an Omega-3 fatty acid lysine salt.	Front Immunol, 16, 1540878 (2025)	https://doi.org/10.3389/fimmu.2025.1540878
  Steigemann, P. et al.	Identification of NUV-244 as a PNPLA3 I148M degrading small molecule.	iScience, 28, 5, 112384 (2025)	https://doi.org/10-1016/j-isci-2025-112384/
  Cowan, KJ. et al.	Recent discussions and proposals on challenging the 3-tier immunogenicity testing strategies from the European Bioanalysis Forum.	Bioanalysis, 17,  9, 575-578 (2025)	https://doi.org/10.1080/17576180.2025.2487377
  Ahmad, S. et al.	Feedback from the 10th European Bioanalysis Forum Young Scientist Symposium and from the Science Café discussions on sustainability in bioanalysis.	Bioanalysis, 17,  8, 509-514 (2025)	https://doi.org/10.1080/17576180.2025.2479963
  Borrallo-Lopez, L. et al.	Combining the zebrafish embryo developmental toxicity assay (ZEDTA) with hemoglobin staining to accelerate the research of novel antimalarial drugs for pregnant women.	Int J Parasitol Drugs Drug Resist 27, 100582 (2025)	https://doi.org/10.1016/j.ijpddr.2025.100582
  von Nussbaum, F. and Testolin, G.	Opening the door to a new treatment paradigm: the re-emergence of chymase inhibitors.	J Med Chem, 68, 6, 6100-6103 (2025)	https://doi.org/10.1021/acs.jmedchem.5c00413
  Garaizar, A. et al.	Perspective on LNP structure and simulation.	Proc Natl Acad Sci USA, 122, 9, e2423433122 (2025)	https://doi.org/10.1073/pnas.2423433122
  Timmerman, P. et al.	Feedback from a workshop by the European Bioanalysis Forum on assay validation requirements for in vitro assays following the publication of ICH M12 guideline – a plea for context-of-use over ICH M10 standards.	Bioanalysis, 17, 6, 379-382 (2025)	https://doi.org/10.1080/17576180.2025.2468596
  Blondeel, E. et al.	The spheroid light microscopy image atlas for morphometrical analysis of three-dimensional cell cultures.	Sci Data, 12, 283 (2025)	https://doi.org/10.1038/s41597-025-04441-x
  Li, H. Z. et al.	Transport and inhibition of the sphingosine-1-phosphate exporter SPNS2.	Nat Commun, 16, 721 (2025)	https://doi.org/10.1038/s41467-025-55942-7

   

• 2024

  Author	Title	Journal	Link
  Goodwin, L. et al.	The use of surrogate matrices in bioanalytical preclinical safety testing using chromatographic methods: a recommendation from the European Bioanalysis forum.	Bioanalysis 16, 1199–1202 (2024)	https://doi.org/10.1080/17576180.2024.2416360
  Arfvidsson, C. et al.	Moving into the cloud: a summary from a European Bioanalysis forum workshop on introducing cloud applications in bioanalytical laboratories.	Bioanalysis 16, 1203–1206 (2024)	https://doi.org/10.1080/17576180.2024.2416357
  Schiedel, M. et al.	We are MedChem: The Frontiers in Medicinal Chemistry 2024.	ChemMedChem 19, e202400543 (2024)	https://doi.org/10.1002/cmdc.202400543
  Hsiao, W.-K. et al.	Opportunities of topical drug products in a changing dermatological landscape.	Eur J Pharm Sci 203, 106913 (2024)	https://doi.org/10.1016/j.ejps.2024.106913
  Hohlbaum, K. et al.	The implementation of tunnel handling in a mouse breeding facility revealed strain-specific behavioural responses.	Lab Anim 58, 552–564 (2024)	https://doi.org/10.1177/00236772231215077
  Li, F. et al.	CACHE Challenge #1: Targeting the WDR Domain of LRRK2, A Parkinson’s Disease Associated Protein.	J Chem Inf Model 64, 8521–8536 (2024)	https://doi.org/10.1021/acs.jcim.4c01267
  Purzner, J. et al.	Ezh2 Delays Activation of Differentiation Genes During Normal Cerebellar Granule Neuron Development and in Medulloblastoma.	Preprint at https://doi org/10 1101/2024 11 21 624171 (2024)	https://doi.org/10.1101/2024.11.21.624171
  Vakalopoulos, A. et al.	Discovery of BAY 2413555, First Selective Positive Allosteric Modulator of the M2 Receptor to Restore Cardiac Autonomic Balance.	J Med Chem 67, 19165–19187 (2024)	https://doi.org/10.1021/acs.jmedchem.4c01590
  Garaizar, A. et al.	Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments.	Proc Natl Acad Sci U S A 121, e2404555121 (2024)	https://doi.org/10.1073/pnas.2404555121
  Streckfuss‐Bömeke, K. et al.	Physiologists as medical scientists: An early warning from the German academic system.	Physiol Rep 12, e70055 (2024)	https://doi.org/10.14814/phy2.70055
  Goodman, J. et al.	Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European Bioanalysis Forum.	Bioanalysis 16, 905–913 (2024)	https://doi.org/10.1080/17576180.2024.2376949
  Cowan, K. J. et al.	The European Bioanalysis Forum recommendation on establishing appropriate drug tolerance levels in antidrug antibody assays.	Bioanalysis 16, 915–921 (2024)	https://doi.org/10.1080/17576180.2024.2376950
  Schaefer, M. et al.	Surface-mutagenesis strategies to enable structural biology crystallization platforms.	Acta Crystallogr D Struct Biol 80, 661–674 (2024)	https://doi.org/10.1107/s2059798324007939
  Rauh, U. et al.	BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.	Nat Cancer 5, 1479–1493 (2024)	https://doi.org/10.1038/s43018-024-00814-0
  Cowan, K. J. et al.	A European Bioanalysis Forum recommendation for requiring a context-of-use statement for successful development and validation of biomarker assays.	Bioanalysis 16, 835–842 (2024)	https://doi.org/10.1080/17576180.2024.2376436
  Gelová, Z. et al.	Protein Binder Toolbox for Studies of Solute Carrier Transporters.	J Mol Biol 436, 168665 (2024)	https://doi.org/10.1016/j.jmb.2024.168665
  Graham, K. et al.	Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.	Cell Chem Biol 31, 1247-1263 e16 (2024)	https://doi.org/10.1016/j.chembiol.2024.02.013
  Hanckmann, E. et al.	Feedback from the Science Café roundtables at the ninth European Bioanalysis Forum Young Scientist Symposium: optimizing the work–life balance in a bioanalytical laboratory.	Bioanalysis 16, 569–574 (2024)	https://doi.org/10.4155/bio-2024-0054
  Karsten, C. B. et al.	Macrophage- and CD4+ T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity.	PLoS Pathog 20, e1012190 (2024)	https://doi.org/10.1371/journal.ppat.1012190
  Begou, O. et al.	An interview with Bioanalysis : speaking with the 2023 Reid bursary award winners – part 2.	Bioanalysis 16, 221–225 (2024)	https://doi.org/10.4155/bio-2024-0051
  Viant, M. R. et al.	Demonstrating the reliability of in vivo metabolomics based chemical grouping: towards best practice.	Arch Toxicol 98, 1111–1123 (2024)	https://doi.org/10.1007/s00204-024-03680-y
  Zenklusen, I. et al.	Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects.	Drugs R D 24, 97–108 (2024)	https://doi.org/10.1007/s40268-024-00456-8
  Wilhelmi, P. et al.	Molecular signatures of angiogenesis inhibitors: a single-embryo untargeted metabolomics approach in zebrafish.	Arch Toxicol 98, 943–956 (2024)	https://doi.org/10.1007/s00204-023-03655-5
  Tug, T. et al.	In vivo alkaline comet assay: Statistical considerations on historical negative and positive control data.	JPT 148, 105583 (2024)	https://doi.org/10.1016/j.yrtph.2024.105583
  Timmerman, P. et al.	Recommendations and Feedback from the European Bioanalysis Forum Workshop: 1 Year Into ICH M10 – Keeping Our Finger on the Pulse.	Bioanalysis 16, 259–270 (2024)	https://doi.org/10.4155/bio-2024-0013
  Sugawara, T. et al.	Dual targeting of the androgen receptor and PI3K / AKT / mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.	Mol Oncol 18, 726–742 (2024)	https://doi.org/10.1002/1878-0261.13577
  Kamp, H. et al.	Utility of in vivo metabolomics to support read-across for UVCB substances under REACH.	Arch Toxicol 98, 755–768 (2024)	https://doi.org/10.1007/s00204-023-03638-6
  Voeltz, D. et al.	A parametric additive hazard model for time-to-event analysis.	BMC Med Res Methodol 24, 48 (2024)	https://doi.org/10.1186/s12874-024-02180-y
  Falkenstern, L. et al.	A miniaturized mode-of-action profiling platform enables high throughput characterization of the molecular and cellular dynamics of EZH2 inhibition	Sci Rep 14, 1739 (2024)	https://doi.org/10.1038/s41598-023-50964-x
  Aquilanti, E. et al.	Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression.	Neuro-oncol Adv 6, vdae115 (2024)	https://doi.org/10.1093/noajnl/vdae115

• 2023

  Author	Title	Journal	Link
  Schneidewind, S. J. et al.	Rumination Detection in Sheep: A Systematic Review of Sensor-Based Approaches.	Animals 13, 3756 (2023)	https://doi.org/10.3390/ani13243756
  Becker, A. et al.	Phase I crossover study of DNA‐protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension.	Clinical Translational Sci 16, 2628–2639 (2023)	https://doi.org/10.1111/cts.13657
  Heller, S. et al.	Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses.	Clin Exp Med 23, 5445–5461 (2023)	https://doi.org/10.1007/s10238-023-01227-6
  Gehringer, M. et al.	Back in Person: Frontiers in Medicinal Chemistry 2023.	ChemMedChem 18, e202300344 (2023)	https://doi.org/10.1002/cmdc.202300344
  Raturi, S. et al.	High-Throughput Expression and Purification of Human Solute Carriers for Structural and Biochemical Studies.	JoVE 65878 (2023)	https://doi.org/10.3791/65878
  Neves, M. et al.	Automatic classification of experimental models in biomedical literature to support searching for alternative methods to animal experiments.	J Biomed Semant 14, 13 (2023)	https://doi.org/10.1186/s13326-023-00292-w
  Langer, G. et al.	Discovery and In Vitro Characterization of BAY 2686013, an Allosteric Small Molecule Antagonist of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor.	Mol Pharm 104, 105–114 (2023)	https://doi.org/10.1124/molpharm.122.000662
  Billié, S. et al.	Identification of unknown impurities J, RRT 2.2, 2.4, 2.6 and 3.4 in tetralysal® capsules.	Eur J Pharm Sci 188, 106519 (2023)	https://doi.org/10.1016/j.ejps.2023.106519
  Yalkinoglu, Ö. et al.	Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates.	Invest New Drugs 41, 596–605 (2023)	https://doi.org/10.1007/s10637-023-01378-z
  Borek, B. et al.	Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy.	Mol Cancer Ther 22, 807–817 (2023)	https://doi.org/10.1158/1535-7163.mct-22-0721
  Ali, A. et al.	European Medicinal Chemistry Leaders in Industry (EMCL) – On the Status and Future of Medicinal Chemistry Research in Europe**	ChemMedChem 18, e202300127 (2023)	https://doi.org/10.1002/cmdc.202300127
  Vakalopoulos, A. et al.	New Generation of sGC Stimulators: Discovery of Imidazo[1,2- a ]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.	J Med Chem 66, 7280–7303 (2023)	https://doi.org/10.1021/acs.jmedchem.2c02082
  Duman, C. et al.	Targeting fatty acid oxidation via Acyl-CoA binding protein hinders glioblastoma invasion.	Cell Death Dis 14, 296 (2023)	https://doi.org/10.1038/s41419-023-05813-0
  Grünewald, S. et al.	Effects of regorafenib on the mononuclear/phagocyte system and how these contribute to the inhibition of colorectal tumors in mice.	Eur J Med Res 28, 147 (2023)	https://doi.org/10.1186/s40001-023-01099-2
  Schnerwitzki, D. et al.	Adapting the pantograph limb: Differential robustness of fore- and hindlimb kinematics against genetically induced perturbation in the neural control networks and its evolutionary implications.	Zoology 157, 126076 (2023)	https://doi.org/10.1016/j.zool.2023.126076
  Göricke, F. et al.	Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21.	Med Chem 66, 3431–3447 (2023)	https://doi.org/10.1021/acs.jmedchem.2c01933
  Zablowsky, N. et al.	High Throughput FISH Screening Identifies Small Molecules That Modulate Oncogenic lncRNA MALAT1 via GSK3B and hnRNPs.	ncRNA 9, 2 (2023)	https://doi.org/10.3390/ncrna9010002
  Orsi, D. L. et al.	Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.	Bioorg Med Chem 78, 117130 (2023)	https://doi.org/10.1016/j.bmc.2022.117130
  Ackloo, S. et al.	Target 2035 – an update on private sector contributions.	RSC Med Chem 14, 1002–1011 (2023)	https://doi.org/10.1039/d2md00441k

   

• 2022

  Author	Title	Journal	Link
  Karwelat, D. et al.	A rodent thyroid-liver chip to capture thyroid toxicity on organ functional level	ALTEX 40, 1 (2022)	https://doi.org/10.14573/altex.2108262
  Heughebaert, L. et al.	Feedback from the 8th European Bioanalysis Forum Young Scientist Symposium	Bioanalysis 14, 1471–1477 (2022)	https://doi.org/10.4155/bio-2022-0232
  Timmerman, P. et al.	Conference report from the European Bioanalysis Forum workshop: toward harmonised implementation of the ICH M10 guideline	Bioanalysis 14, 22, 1407–1411 (2022)	https://doi.org/10.4155/bio-2022-0229
  Bertani, V. et al.	Artificial intelligence in toxicological pathology: quantitative evaluation of compound-induced follicular cell hypertrophy in rat thyroid gland using deep learning models	Toxicol Pathol 50, 1, 23–34 (2021)	https://doi.org/10.1177/01926233211052010
  Novak, B. et al.	Clinical pharmacokinetics and safety of a 10% aminolevulinic acid hydrochloride nanoemulsion gel (BF‐200 ALA) in photodynamic therapy of patients extensively affected with actinic keratosis: results of 2 maximal usage pharmacokinetic trials	Clinical Pharm in Drug Dev 11, 4, 535–550 (2022)	https://doi.org/10.1002/cpdd.1023
  Müller, S.et al.	Target 2035 – update on the quest for a probe for every protein	RSC Med Chem 13, 13–21 (2022)	https://doi.org/10.1039/D1MD00228G
  Hillig, R. C. & Bader, B.	Targeting RAS oncogenesis with SOS1 inhibitors	Advances in Cancer Research vol. 153 169–203 (Elsevier, 2022)	https://doi.org/10.1016/bs.acr.2021.07.001
  Henß, T. et al.	Optogenetic tools for manipulation of cyclic nucleotides functionally coupled to cyclic nucleotide‐gated channels	British J Pharmacology 179, 11, 2519–2537 (2022)	https://doi.org/10.1111/bph.15445
  Schüssele, L. M. et al.	Establishment of a novel method to assess MEK1/2 inhibition in PBMCs for clinical drug development	Front Cell Dev Biol 10, 1063692 (2022)	https://doi.org/10.3389/fcell.2022.1063692
  Billié, S. et al.	Completion of the impurity profile of lymecycline: formal identification of impurities E and F	Journal of Pharmaceutical and Biomedical Analysis 220, 114993 (2022)	https://doi.org/10.1016/j.jpba.2022.114993
  Orsi, D. L. et al.	Discovery and structure-based design of potent covalent PPARγ inverse-agonists BAY-4931 and BAY-0069	J Med Chem 65, 21, 14843–14863 (2022)	https://doi.org/10.1021/acs.jmedchem.2c01379
  Diamanti, E. et al.	Frontiers in medicinal chemistry 2022 goes virtual	ChemMedChem 17, 21, e202200419 (2022)	https://doi.org/10.1002/cmdc.202200419
  Boiteau, J..G. et al.	Complete [1H], [13C] and [15N] assignments of the minor isomer of codeine N‐oxide	Magnetic Reson in Chemistry 60, 12, 1185–1188 (2022)	https://doi.org/10.1002/mrc.5302
  Cowan, K. J. et al.	Biomarker context-of-use: how organisational design can impact the implementation of the appropriate biomarker assay strategy	Bioanalysis 14, 13, 911–917 (2022)	https://doi.org/10.4155/bio-2022-0143
  Pla, L. et al.	Protocols for the evaluation of neurodevelopmental alterations in rabbit models in vitro and in vivo	Front Toxicol 4, 918520 (2022)	https://doi.org/10.3389/ftox.2022.918520
  Regan, J. L. et al.	Identification of a neural development gene expression signature in colon cancer stem cells reveals a role for EGR2 in tumorigenesis	iScience 25, 7, 104498 (2022)	https://doi.org/10.1016/j.isci.2022.104498
  Hohlbaum, K. et al.	Effects of separated pair housing of female C57BL/6JRj mice on well-being	Sci Rep 12, 8819 (2022)	https://doi.org/10.1038/s41598-022-12846-6
  Alborzinia, H. et al.	MYCN mediates cysteine addiction and sensitises neuroblastoma to ferroptosis	Nat Cancer 3, 471–485 (2022)	https://doi.org/10.1038/s43018-022-00355-4
  Chume, F. C. et al.	Glycated albumin in diabetes mellitus: a meta-analysis of diagnostic test accuracy	Clinical Chemistry and Laboratory Medicine (CCLM) 60, 7, 961–974 (2022)	https://doi.org/10.1515/cclm-2022-0105
  Del Amo, E. M. et al.	Ocular metabolism and distribution of drugs in the rabbit eye: quantitative assessment after intracameral and intravitreal administrations	International Journal of Pharmaceutics 613, 121361 (2022)	https://doi.org/10.1016/j.ijpharm.2021.121361
  Speck, D. et al.	Expression and characterisation of relaxin family peptide receptor 1 variants	Front Pharmacol 12, 826112 (2022)	https://doi.org/10.3389/fphar.2021.826112
  Lerchen, H.-G. et al.	A small molecule–drug conjugate (SMDC) consisting of a modified camptothecin payload linked to an αVß3 binder for the treatment of multiple cancer types	Cancers 14, 2, 391 (2022)	https://doi.org/10.3390/cancers14020391

• 2021

  Author	Title	Journal	Link
  Bannik, K. et al.	DNA repair inhibitors sensitise cells differently to high and low LET radiation	Sci Rep 11, 23257 (2021)	https://doi.org/10.1038/s41598-021-02719-9
  Peirsman, A. et al.	MISpheroID: a knowledgebase and transparency tool for minimum information in spheroid identity	Nat Methods 18, 1294–1303 (2021)	https://doi.org/10.1038/s41592-021-01291-4
  Wortmann, L. et al.	Discovery and characterisation of the potent and highly selective 1,7-naphthyridine-based inhibitors BAY-091 and BAY-297 of the kinase PIP4K2A	J Med Chem 64, 21, 15883–15911 (2021)	https://doi.org/10.1021/acs.jmedchem.1c01245
  Klaus, M. et al.	Ultrahigh‐throughput detection of enzymatic alcohol dehydrogenase activity in microfluidic droplets with a direct fluorogenic assay	ChemBioChem 22, 23, 3292–3299 (2021)	https://doi.org/10.1002/cbic.202100322
  Davenport, A. J. et al.	Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers	Sci Rep 11, 19877 (2021)	https://doi.org/10.1038/s41598-021-99177-0
  Timmerman, P. et al.	Recommendations and discussion points on immunogenicity, biomarkers, automation/technology and protein–MS From the 2021 European Bioanalysis Forum focus workshops	Bioanalysis 13, 19, 1459–1465 (2021)	https://doi.org/10.4155/bio-2021-0200
  Doleschel, D. et al.	Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumour regrowth	J Exp Clin Cancer Res 40, 288 (2021)	https://doi.org/10.1186/s13046-021-02043-0
  Munday, C. et al.	Feedback from the Science Café at the 7th European Bioanalysis Forum Young Scientist Symposium	Bioanalysis 13, 24, 1793-1798 (2021)	https://doi.org/10.4155/bio-2021-0187
  Gradl, S. et al.	Discovery of the SMYD3 inhibitor BAY-6035 using thermal shift assay (TSA)-based high-throughput screening	SLAS Discov 26, 8, 947–960 (2021)	https://doi.org/10.1177/24725552211019409
  Berger, M. et al.	BAY-8400: a novel potent and selective DNA-PK inhibitor which shows synergistic efficacy in combination with targeted alpha therapies	J Med Chem 64, 17,  12723–12737 (2021)	https://doi.org/10.1021/acs.jmedchem.1c00762
  Port, A. et al.	Phase 1 study in healthy participants of the safety, pharmacokinetics and pharmacodynamics of Enpatoran (M5049), a dual antagonist of toll‐like receptors 7 and 8	Pharmacology Res & Perspec 9, 5, e00842 (2021)	https://doi.org/10.1002/prp2.842
  Dieter, S. M. et al.	Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer	Cell Reports 36, 3, 109394 (2021)	https://doi.org/10.1016/j.celrep.2021.109394
  Garvie, C. W. et al.	Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase	Nat Commun 12, 4375 (2021)	https://doi.org/10.1038/s41467-021-24495-w
  Witte, F. et al.	A trans locus causes a ribosomopathy in hypertrophic hearts that affects mRNA translation in a protein length-dependent fashion	Genome Biol 22, 191 (2021)	https://doi.org/10.1186/s13059-021-02397-w
  Krause, B. C. et al.	Combinatory effects of cerium dioxide nanoparticles and acetaminophen on the liver — a case study of low-dose interactions in human HuH-7 cells	IJMS 22, 13, 6866 (2021)	https://doi.org/10.3390/ijms22136866
  Regan, J. L. et al.	RNA sequencing of long-term label-retaining colon cancer stem cells identifies novel regulators of quiescence	iScience 24, 6, 102618 (2021)	https://doi.org/10.1016/j.isci.2021.102618
  Kammertoens, T. et al.	Breeding and maintenance of immunodeficient mouse lines under SPF conditions — a call for individualised severity analyses and approval procedures	Animals 11, 6, 1789 (2021)	https://doi.org/10.3390/ani11061789
  Lücking, U. et al.	Changing for the better: discovery of the highly potent and selective CDK9 inhibitor VIP152 suitable for once weekly intravenous dosing for the treatment of cancer	J Med Chem 64, 15, 11651–11674 (2021)	https://doi.org/10.1021/acs.jmedchem.1c01000
  Taavitsainen, P. et al.	Metabolism and mass balance of the novel nonsteroidal androgen receptor inhibitor darolutamide in humans	Drug Metab Dispos 49, 6, 420–433 (2021)	https://doi.org/10.1124/dmd.120.000309
  Suominen, M. I. et al.	Additive benefits of radium-223 dichloride and Bortezomib combination in a systemic multiple myeloma mouse model	IJMS 22, 11, 5570 (2021)	https://doi.org/10.3390/ijms22115570
  Hahn, M. G. et al.	Discovery of the soluble guanylate cyclase activator Runcaciguat (BAY 1101042)	J Med Chem 64, 9, 5323–5344 (2021)	https://doi.org/10.1021/acs.jmedchem.0c02154
  Delahaye, L. et al.	Feedback from the sixth European Bioanalysis Forum Young Scientist Symposium	Bioanalysis 13, 9, 669–674 (2021)	https://doi.org/10.4155/bio-2021-0051
  Ede, S. et al.	Improved diazo-transfer reaction for DNA-encoded chemistry and its potential application for macrocyclic DEL-libraries	Molecules 26, 6,  1790 (2021)	https://doi.org/10.3390/molecules26061790
  Liu, D. et al.	Nickel‐catalysed N‐arylation of NH‐sulfoximines with aryl halides via paired electrolysis	Angew Chem Int Ed 60, 17,  9444–9449 (2021)	https://doi.org/10.1002/anie.202016310
  Calogero, S. et al.	Feedback from the Science Café from the sixth European Bioanalysis Forum Young Scientist Symposium	Bioanalysis 13, 3, 129–133 (2021)	https://doi.org/10.4155/bio-2021-0017
  Sutherland, M. et al.	Rational design and synthesis of selective PRMT4 inhibitors: a new chemotype for development of cancer therapeutics	ChemMedChem 16, 7, 1116–1125 (2021)	https://doi.org/10.1002/cmdc.202100018
  Moosmayer, D. et al.	Crystal structures of the selenoprotein glutathione peroxidase 4 in its apo form and in complex with the covalently bound inhibitor ML162	Acta Crystallogr D Struct Biol 77, 2, 237–248 (2021)	https://doi.org/10.1107/S2059798320016125
  Lemos, C. et al.	The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models	Cell Oncol 44, 581–594 (2021)	https://doi.org/10.1007/s13402-020-00584-8
  Pischon, H. et al.	Artificial intelligence in toxicologic pathology: quantitative evaluation of compound-induced hepatocellular hypertrophy in rats	Toxicol Pathol 49, 4, 928–937 (2021)	https://doi.org/10.1177/0192623320983244
  Lissy, M. et al.	Thorough QT/QTc study evaluating the effect of macimorelin on cardiac safety parameters in healthy participants	Clinical Pharm in Drug Dev 10, 5, 494–501 (2021)	https://doi.org/10.1002/cpdd.872
  Atilaw, Y. et al.	Solution conformations shed light on PROTAC cell permeability	ACS Med Chem Lett 12, 1, 107–114 (2021)	https://doi.org/10.1021/acsmedchemlett.0c00556

• 2020

  Author	Title	Journal	Link
  Hillisch, A. et al.	Design, synthesis and pharmacological characterisation of a neutral, non-prodrug thrombin inhibitor with good oral pharmacokinetics	J Med Chem 63, 21, 12574–12594 (2020)	https://doi.org/10.1021/acs.jmedchem.0c01035
  Goodman, J. et al.	Update to the European Bioanalysis Forum recommendation on biomarkers assays: bringing context of use into practice	Bioanalysis 12, 1427–1437 (2020)	https://doi.org/10.4155/bio-2020-0243
  Agueusop, I. et al.	Short-term variability of the human serum metabolome depending on nutritional and metabolic health status	Sci Rep 10, 16310 (2020)	https://doi.org/10.1038/s41598-020-72914-7
  Lemos, C. et al.	Identification of small molecules that modulate mutant p53 condensation	iScience 23, 11, 101517 (2020)	https://doi.org/10.1016/j.isci.2020.101517
  Panknin, O. et al.	Discovery and characterisation of BAY 1214784, an orally available spiroindoline derivative acting as a potent and selective antagonist of the human gonadotropin-releasing hormone receptor as proven in a first-in-human study in postmenopausal women	J Med Chem 63, 20, 11854–11881 (2020)	https://doi.org/10.1021/acs.jmedchem.0c01076
  Werbeck, N. D. et al.	A distal regulatory region of a class I human histone deacetylase	Nat Commun 11, 3841 (2020)	https://doi.org/10.1038/s41467-020-17610-w
  Zhao, X.-Y. et al.	Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia	Nat Commun 11, 2992 (2020)	https://doi.org/10.1038/s41467-020-16720-9
  Lücking, U. et al.	Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumour models	J Med Chem 63, 13, 7293–7325 (2020)	https://doi.org/10.1021/acs.jmedchem.0c00369
  Schulze, V. K. et al.	Treating cancer by spindle assembly checkpoint abrogation: discovery of two clinical candidates, BAY 1161909 and BAY 1217389, targeting MPS1 kinase	J Med Chem 63, 15, 8025–8042 (2020)	https://doi.org/10.1021/acs.jmedchem.9b02035
  Timmerman, P. et al.	European Bioanalysis Forum feedback on draft ICH M10 guideline on bioanalytical method validation during the step 2b public consultation period	Bioanalysis 12, 1–11 (2020)	https://doi.org/10.4155/bio-2020-0065
  Klaus, B. et al.	Safety, tolerability, pharmacokinetics and pharmacodynamics of Macimorelin in healthy adults: results of a single-dose, randomised controlled study	Growth Hormone & IGF Research 52, 101321 (2020)	https://doi.org/10.1016/j.ghir.2020.101321
  Mortier, J. et al.	Computationally empowered workflow identifies novel covalent allosteric binders for KRASG12C	ChemMedChem 15, 10, 827–832 (2020)	https://doi.org/10.1002/cmdc.201900727
  Eaton, J. K. et al.	Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles	Nat Chem Biol 16, 497–506 (2020)	https://doi.org/10.1038/s41589-020-0501-5
  Wu, X. et al.	Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and Schlafen family member 12	J Biol Chem 295, 11, 3431–3446 (2020)	https://doi.org/10.1074/jbc.RA119.011191
  Taavitsainen, P. et al.	Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats	Xenobiotica 50, 8, 967–979 (2020)	https://doi.org/10.1080/00498254.2020.1723038
  Brzezinka, K. et al.	Characterisation of the menin-MLL interaction as therapeutic cancer target	Cancers (Basel) 12, 1, 201 (2020)	https://doi.org/10.3390/cancers12010201
  Parker, V. E. R. et al.	Efficacy, safety and mechanistic insights of Cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist	The Journal of Clinical Endocrinology & Metabolism 105, 803–820 (2020)	https://doi.org/10.1210/clinem/dgz047
  Lefranc, J. et al.	Discovery of BAY-985, a highly selective TBK1/IKKε inhibitor	J Med Chem 63, 601–612 (2020)	https://doi.org/10.1021/acs.jmedchem.9b01460
  Wengner, A. M. et al.	The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models	Mol Cancer Ther 19, 1, 26–38 (2020)	https://doi.org/10.1158/1535-7163.MCT-19-0019

• 2019

  Author	Title	Journal	Link
  Werner, S. et al.	Discovery and characterisation of the potent and selective P2X4 inhibitor N-[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and structure-guided amelioration of its CYP3A4 induction profile	J Med Chem 62, 24, 11194–11217 (2019)	https://doi.org/10.1021/acs.jmedchem.9b01304
  Pihl, S. et al.	EBF recommendation on practical management of critical reagents for antidrug antibody ligand-binding assays	Bioanalysis 11, 19, 1787–1798 (2019)	https://doi.org/10.4155/bio-2019-0248
  Lewis, T. A. et al.	Optimisation of PDE3A modulators for SLFN12-dependent cancer cell killing	ACS Med Chem Lett 10, 11, 1537–1542 (2019)	https://doi.org/10.1021/acsmedchemlett.9b00360
  Zurth, C. et al.	Drug-drug interaction potential of darolutamide: in vitro and clinical studies	Eur J Drug Metab Pharmacokinet 44, 747–759 (2019)	https://doi.org/10.1007/s13318-019-00577-5
  Shore, N. et al.	Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial	Target Oncol 14, 527–539 (2019)	https://doi.org/10.1007/s11523-019-00674-0
  Protti, M. et al.	Feedback from the fifth European Bioanalysis Forum Young Scientist Symposium	Bioanalysis 11, 16, 1453–1458 (2019)	https://doi.org/10.4155/bio-2019-0206
  Brzezinka, K. et al.	Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia	J Hematol Oncol 12, 66 (2019)	https://doi.org/10.1186/s13045-019-0749-y
  Renders, L. et al.	First-in-human phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis	PLoS ONE 14, e0212023 (2019)	https://doi.org/10.1371/journal.pone.0212023
  Grünewald, S. et al.	Rogaratinib: a potent and selective pan-FGFR inhibitor with broad antitumour activity in FGFR-overexpressing preclinical cancer models	Int J Cancer 145, 5, 1346–1357 (2019)	https://doi.org/10.1002/ijc.32224
  Siemeister, G. et al.	Inhibition of BUB1 kinase by BAY 1816032 sensitises tumour cells toward taxanes, ATR and PARP inhibitors in vitro and in vivo	Clin Cancer Res 25, 4, 1404–1414 (2019)	https://doi.org/10.1158/1078-0432.CCR-18-0628
  Zahner, C. et al.	No clinically relevant interactions of St. John's wort extract Ze 117 low in hyperforin with cytochrome P450 enzymes and P‐glycoprotein	Clin Pharma and Therapeutics 106, 2, 432–440 (2019)	https://doi.org/10.1002/cpt.1392
  Vriens, K. et al.	Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity	Nature 566, 403–406 (2019)	https://doi.org/10.1038/s41586-019-0904-1
  Hillig, R. C. et al.	Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction	Proc Natl Acad Sci U S A 116, 7, 2551–2560 (2019)	https://doi.org/10.1073/pnas.1812963116
  Wilson, A. et al.	European Bioanalysis Forum recommendation on the best practices to demonstrate processed sample stability	Bioanalysis 11, 1, 7–11 (2019)	https://doi.org/10.4155/bio-2018-0271
  Nguyen, D. et al.	Discovery and characterisation of the potent and highly selective (piperidin-4-yl)pyrido[3,2- d]pyrimidine based in vitro probe BAY-885 for the kinase ERK5	J Med Chem 62, 2,928–940 (2019)	https://doi.org/10.1021/acs.jmedchem.8b01606

• 2018

  Author	Title	Journal	Link
  Kall, M. A. et al.	Incurred sample reproducibility: 10 years of experiences: views and recommendations from the European Bioanalysis Forum	Bioanalysis 10, 21, 1723–1732 (2018)	https://doi.org/10.4155/bio-2018-0194
  Quanz, M. et al.	Preclinical efficacy of the novel monocarboxylate transporter 1 inhibitor BAY-8002 and associated markers of resistance	Mol Cancer Ther 17, 11, 2285–2296 (2018)	https://doi.org/10.1158/1535-7163.MCT-17-1253
  Timmerman, P. et al.	Toward decision-based acceptance criteria for bioanalytical method validation: a proposal for discussion from the European Bioanalysis Forum	Bioanalysis 10, 16, 1255–1259 (2018)	https://doi.org/10.4155/bio-2018-0131
  Klutzny, S. et al.	PDE5 inhibition eliminates cancer stem cells via induction of PKA signalling	Cell Death Dis 9, 192 (2018)	https://doi.org/10.1038/s41419-017-0202-5
  Goodman, J. et al.	Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles	Bioanalysis 10, 8, 197–204 (2018)	https://doi.org/10.4155/bio-2017-4971
  Schultze-Mosgau, M.-H. et al.	Characterisation of the pharmacokinetics of Vilaprisan: Bioavailability, excretion, biotransformation and drug-drug interaction potential	Clin Pharmacokinet 57, 1001–1015 (2018)	https://doi.org/10.1007/s40262-017-0607-4

• 2017

  Author	Title	Journal	Link
  Lücking, U. et al.	Identification of Atuveciclib (BAY 1143572), the first highly selective, clinical PTEFb/CDK9 inhibitor for the treatment of cancer	ChemMedChem 12, 21, 1776–1793 (2017)	https://doi.org/10.1002/cmdc.201700447
  Ellermann, M. et al.	Novel class of potent and cellularly active inhibitors devalidates MTH1 as broad-spectrum cancer target	ACS Chem Biol 12, 8, 1986–1992 (2017)	https://doi.org/10.1021/acschembio.7b00370
  Willuda, J. et al.	Preclinical antitumour efficacy of BAY 1129980 - a novel Auristatin-based anti-C4.4A (LYPD3) antibody-drug conjugate for the treatment of non-small cell lung cancer	Mol Cancer Ther 16, 5, 893–904 (2017)	https://doi.org/10.1158/1535-7163.MCT-16-0474
  Undre, N. & Dickinson, J.	Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants	BMJ Open 7, 4, e012252 (2017)	https://doi.org/10.1136/bmjopen-2016-012252
  Santag, S. et al.	BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumour activity	Cancer Lett 390, 21–29 (2017)	https://doi.org/10.1016/j.canlet.2016.12.029
  Klutzny, S. et al.	Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumour cell death	Cell Death Dis 8, e2709 (2017)	https://doi.org/10.1038/cddis.2017.130
  Basit, F. et al.	Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells	Cell Death Dis 8, e2716 (2017)	https://doi.org/10.1038/cddis.2017.133
  Ericzon, B. et al.	Pharmacokinetics of prolonged‐release tacrolimus versus immediate‐release tacrolimus in de novo liver transplantation: a randomised phase III substudy	Clinical Transplantation 31, 6,  e12958 (2017)	https://doi.org/10.1111/ctr.12958
  Pusch, S. et al.	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo	Acta Neuropathol 133, 629–644 (2017)	https://doi.org/10.1007/s00401-017-1677-y
  Politz, O. et al.	BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signalling-dependent tumour growth in mouse models	Int J Cancer 140, 2, 449–459 (2017)	https://doi.org/10.1002/ijc.30457

• 2016

  Author	Title	Journal	Link
  Sommer, A. et al.	Preclinical efficacy of the Auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors	Cancer Res 76, 21, 6331–6339 (2016	https://doi.org/10.1158/0008-5472.CAN-16-0180
  Schütt, B. et al.	Pharmacodynamics and safety of the novel selective progesterone receptor modulator Vilaprisan: a double-blind, randomised, placebo-controlled phase 1 trial in healthy women	Hum Reprod 31, 8, 1703–1712 (2016)	https://doi.org/10.1093/humrep/dew140
  Eggert, E. et al.	Discovery and characterisation of a highly potent and selective aminopyrazoline-based in vivo probe (BAY-598) for the protein lysine methyltransferase SMYD2	J Med Chem 59, 10, 4578–4600 (2016)	https://doi.org/10.1021/acs.jmedchem.5b01890
  Kapoor, K. et al.	Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amides	Proc Natl Acad Sci U S A 113, 17, 4711–4716 (2016)	https://doi.org/10.1073/pnas.1603735113
  Wengner, A. M. et al.	Novel Mps1 kinase inhibitors with potent antitumour activity	Mol Cancer Ther 15, 4, 583–592 (2016)	https://doi.org/10.1158/1535-7163.MCT-15-0500
  Reynoird, N. et al.	Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer	Genes Dev 30, 7, 772–785 (2016)	https://doi.org/10.1101/gad.275529.115
  Baron, A. P. et al.	Probing the catalytic functions of BUB1 kinase using the small molecule inhibitors BAY-320 and BAY-524	Elife 5, e12187 (2016)	https://doi.org/10.7554/eLife.12187
  Hernando, H. et al.	EZH2 inhibition blocks multiple myeloma cell growth through upregulation of epithelial tumour suppressor genes	Mol Cancer Ther 15, 2,  287–298 (2016)	https://doi.org/10.1158/1535-7163.MCT-15-0486
  Ferreira de Freitas, R. et al.	Discovery of a potent class I protein arginine methyltransferase fragment inhibitor	J Med Chem 59, 3, 1176–1183 (2016)	https://doi.org/10.1021/acs.jmedchem.5b01772
  Sugawara, T. et al.	BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients	Oncotarget 7, 6015–6028 (2016)	https://doi.org/10.18632/oncotarget.6864
  Hartung, I. V. et al.	Optimisation of allosteric MEK inhibitors. Part 2: taming the sulfamide group balances compound distribution properties	Bioorg Med Chem Lett 26, 1,  186–193 (2016)	https://doi.org/10.1016/j.bmcl.2015.11.004

• 2015

  Author	Title	Journal	Link
  Luense, S. et al.	Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors	J Biomol Screen 20, 2, 190–201 (2015)	https://doi.org/10.1177/1087057114559668
  Meier, J. C. et al.	Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumour growth delay in the chemoresistant ovarian cancer model A2780cis	Cancer Med 4, 2, 253–267 (2015)	https://doi.org/10.1002/cam4.354
  Schulze, J. et al.	Cell-based protein stabilisation assays for the detection of interactions between small-molecule inhibitors and BRD4	J Biomol Screen 20, 2, 180–189 (2015)	https://doi.org/10.1177/1087057114552398
  von Nussbaum, F. and Süssmuth, R. D.	Multiple attack on bacteria by the new antibiotic teixobactin	Angew Chem Int Ed Engl 54, 23, 6684–6686 (2015)	https://doi.org/10.1002/anie.201501440
  von Nussbaum, F. et al.	Freezing the bioactive conformation to boost potency: the identification of BAY 85-8501, a selective and potent inhibitor of human neutrophil elastase for pulmonary diseases	Chem Med Chem 10, 7, 1163–1173 (2015)	https://doi.org/10.1002/cmdc.201500131
  Gentili, C. et al.	Chromosome missegregation associated with RUVBL1 deficiency	PLoS One 10, 7, e0133576 (2015)	https://doi.org/10.1371/journal.pone.0133576
  Nakamaru, Y. et al.	Investigation of potential pharmacokinetic interactions between Teneligliptin and Metformin in steady-state conditions in healthy adults	Clinical Therapeutics 37, 9, 2007–2018 (2015)	https://doi.org/10.1016/j.clinthera.2015.06.012
  von Nussbaum, F. and Li, V. M.-J.	Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: into clinical testing with pre-adaptive pharmacophores	Bioorg Med Chem Lett 25, 20, 4370–4381 (2015)	https://doi.org/10.1016/j.bmcl.2015.08.049
  Wenzel, C. et al.	A novel 3D high-content assay identifies compounds that prevent fibroblast invasion into tissue surrogates	Exp Cell Res 339, 1, 35–43 (2015)	https://doi.org/10.1016/j.yexcr.2015.10.003
  Hartung, I. V. et al.	Modular assembly of allosteric MEK inhibitor structural elements unravels potency and feedback-modulation handles	Chem Med Chem 10, 12, 2004–2013 (2015)	https://doi.org/10.1002/cmdc.201500442